AIM ImmunoTech (AIM) announces NYSE delisting, plans to appeal

AIM ImmunoTech Inc. (“AIM” or the “Company”) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, reported that on April 4, 2025, it received notification from NYSE Regulation of the NYSE American LLC (the “NYSE American” or the “Exchange”) that it had suspended trading of the Company’s common stock and of its determination to commence delisting proceedings of the Company’s common stock from the Exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company’s common stock. The Company plans to appeal the determination to the Exchange’s Listing Qualifications Panel, although there can be no assurance that any such appeal will be successful.

The Company’s common stock is expected to begin trading on the Pink Open Market on April 7, 2025.

Additional details are included in, and the description above is qualified in its entirety by, AIM’s Current Report on Form 8-K filed with the SEC on April 4, 2025, which will be made available under “Investors” – “SEC Filings” at aimimmuno.com.

You May Also Be Interested In

• Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
• Castle Biosciences gains dual listing on Nasdaq Texas
• Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'